Holen Sie sich die Stockscreener-App
39.00
4.01%
-1.63
Handel nachbörslich:
38.74
-0.26
-0.67%
Schlusskurs vom Vortag:
$40.63
Offen:
$40.18
24-Stunden-Volumen:
990.21K
Relative Volume:
0.93
Marktkapitalisierung:
$2.41B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-229.97M
KGV:
-9.0207
EPS:
-4.3234
Netto-Cashflow:
$-136.51M
1W Leistung:
+15.86%
1M Leistung:
+56.88%
6M Leistung:
+166.21%
1J Leistung:
+1,560%
1-Tages-Spanne:
$38.80
$41.93
1-Wochen-Bereich:
$33.51
$44.30
52-Wochen-Spanne:
$1.92
$45.60
Kodiak Sciences Inc Stock (KOD) Company Profile
Firmenname
Kodiak Sciences Inc
Sektor
Branche
Telefon
650-281-0850
Adresse
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
39.00 | 2.51B | 0 | -229.97M | -136.51M | -4.3234 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-11 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-09-25 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-09-22 | Eingeleitet | Jefferies | Buy |
| 2025-08-14 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-05 | Eingeleitet | H.C. Wainwright | Neutral |
| 2023-12-11 | Fortgesetzt | Goldman | Sell |
| 2023-11-17 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-07-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-07-25 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-07-24 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-07-24 | Herabstufung | Jefferies | Buy → Hold |
| 2022-11-15 | Eingeleitet | CapitalOne | Overweight |
| 2022-08-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-02-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2022-02-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-02-17 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-12-11 | Eingeleitet | Citigroup | Neutral |
| 2020-11-30 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-11-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-03 | Eingeleitet | Goldman | Buy |
| 2020-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-02-06 | Eingeleitet | SunTrust | Buy |
| 2020-01-08 | Eingeleitet | ROTH Capital | Buy |
| 2020-01-03 | Eingeleitet | Jefferies | Buy |
| 2019-12-24 | Eingeleitet | JP Morgan | Overweight |
| 2019-10-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2018-10-29 | Eingeleitet | Barclays | Overweight |
| 2018-10-29 | Eingeleitet | BofA/Merrill | Buy |
| 2018-10-29 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Kodiak Sciences Inc Aktie (KOD) Neueste Nachrichten
Kodiak Sciences Insider Sold Shares Worth $1,197,488, According to a Recent SEC Filing - marketscreener.com
Kodiak climbs on late-stage trial win for diabetic retinopathy therapy - MSN
Kodiak Sciences | 10-K: FY2025 Annual Report - Moomoo
Kodiak Sciences Faces Going Concern Warning As Valuation Gap Persists - Sahm
Lifesci Capital Trims Earnings Outlook for Kodiak Sciences - National Today
Q1 EPS Estimates for Kodiak Sciences Decreased by Analyst - marketbeat.com
Lifesci Capital Forecasts Lower Earnings for Kodiak Sciences - marketbeat.com
Kodiak Sciences CFO Borgeson sells $1.2m in shares By Investing.com - Investing.com India
Kodiak Sciences CFO Borgeson sells $1.2m in shares - Investing.com
Kodiak Sciences (KOD) CFO exercises 30K options and sells 30K shares under 10b5-1 plan - Stock Titan
Kodiak Sciences Inc. (KOD) stock price, news, quote and history - Yahoo Finance UK
[144] Kodiak Sciences Inc. SEC Filing - Stock Titan
Point72 reports 609,806 shares in Kodiak (KOD) — 1.0% stake - Stock Titan
Kodiak Sciences Inc. (KOD) options chain - Yahoo Finance Singapore
Kodiak Sciences (KOD) Sees Decline as Stock Falls 8.7% - gurufocus.com
Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation - Moomoo
Kodiak Sciences Inc. (KOD) Latest Stock News & Headlines - Yahoo! Finance Canada
Fed Meeting: Can Kodiak Sciences Inc lead its sector in growthQuarterly Market Summary & Breakout Confirmation Trade Signals - baoquankhu1.vn
Kodiak Sciences 2025 Financial Update - AlphaStreet
Kodiak Sciences (KOD) Reports Positive Developments in Q4 Results - GuruFocus
Kodiak Sciences (KOD) Shares Surge Over 10% - GuruFocus
Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus - TradingView
Kodiak Sciences Stock Soars Amid Positive Phase 3 Findings - StocksToTrade
Kodiak Sciences Stock (KOD) Rallies as Analysts Weigh In After Earnings - TipRanks
Why Kodiak Sciences Stock Is Suddenly Surging - TipRanks
Kodiak Sciences (NASDAQ:KOD) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS - marketbeat.com
Kodiak Sciences Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Kodiak Sciences (NASDAQ: KOD) outlines retinal pipeline and going-concern risk - stocktitan.net
Phase 3 win and 2027 cash runway for Kodiak Sciences (NASDAQ: KOD) - stocktitan.net
Kodiak Sciences Q4 net loss widens on higher R&D spending - TradingView
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - Bitget
BRIEF-Kodiak Sciences Q4 Net Income USD -56.736 Million - TradingView
Kodiak Sciences (NASDAQ:KOD) Trading 8.3% HigherHere's Why - marketbeat.com
Kodiak Sciences stock is surging Friday: What's driving the action? - MSN
Kodiak Sciences (KOD) climbs 75% on stellar clinical results - msn.com
Kodiak Sciences stock hits 52-week highhere's why - MSN
MACD Signal: Can Kodiak Sciences Inc grow without dilution2026 Risk Factors & Real-Time Volume Spike Alerts - baoquankhu1.vn
Kodiak Sciences Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Kodiak Sciences (NASDAQ:KOD) Trading Down 7.8%Time to Sell? - marketbeat.com
Kodiak Sciences: Road To $120 - Forbes
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing - AOL.com
Kodiak Sciences (KOD) Is Up 66.3% After Strong Zenkuda GLOW2 Phase 3 DataHas The Bull Case Changed? - Yahoo Finance
Kodiak Sciences (KOD) Is Up 66.3% After Zenkuda’s Phase 3 Win in Diabetic Retinopathy - simplywall.st
Kodiak Sciences (KOD) CEO exercises 300,000 stock options into common shares - Stock Titan
KOD Shares Surge Following Encouraging Phase III Results for Eye Disorder Treatment Candidate - Bitget
KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate - The Globe and Mail
H.C. Wainwright raises Kodiak Sciences stock price target on trial data - Investing.com UK
Kodiak Sciences: A Promising Breakthrough in Diabetic Retinopathy Trials - timothysykes.com
Kodiak Sciences (NASDAQ:KOD) Shares Gap Up After Analyst Upgrade - MarketBeat
Kodiak Sciences (NASDAQ:KOD) Price Target Raised to $80.00 - MarketBeat
Kodiak Sciences: Shares Up On Positive Eye Disease DataBut I Remain On Sidelines (KOD) - Seeking Alpha
Finanzdaten der Kodiak Sciences Inc-Aktie (KOD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):